Trial Profile
Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous Bolus) and Constant Intravenous Infusion Over 7 Days of GSK3335065 in Healthy Adult Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK-3335065 (Primary)
- Indications Pancreatitis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 30 Jul 2021 Results assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK3335065 in healthy volunteers, published in the British Journal of Clinical Pharmacology.
- 05 Jun 2018 Planned End Date changed from 11 Jul 2018 to 18 Jul 2019.
- 05 Jun 2018 Planned primary completion date changed from 11 Jul 2018 to 18 Jul 2019.